Abstract
Background Individuals surviving TB disease may experience chronic sequelae that reduce survival and quality-of-life. These post-TB sequalae are not generally considered in estimates of the health impact of TB disease. We estimated reductions in life expectancy and quality-adjusted life expectancy for individuals developing TB disease in the United States, including post-TB sequelae.
Methods We extracted national surveillance data on individuals diagnosed with TB during 2015-2019, including demographics, vital status at diagnosis, treatment duration, treatment outcome, and co-prevalent conditions. Using a mathematical model we simulated life expectancy and quality-adjusted life-years (QALYs) for the TB cohort, as compared to a no-TB counterfactual. We disaggregated results to report the proportion due to post-TB sequelae, and stratified outcomes by age, sex, and race.
Findings Estimated life expectancy after TB diagnosis was 30.3 (95% uncertainty interval: 29.9, 30.7) years for the TB cohort versus 32.3 (31.9, 32.7) without TB, a difference of 2.03 (1.84, 2.21) years and 1.93 (1.69, 2.18) QALYs. Life-years lost were greatest for 65-74-year-olds versus other age groups, for men versus women, and for American Indian or Alaska Native individuals versus persons from other race/ethnicities. Overall, 41% (35, 46) of life-years and 48% (42, 54) of QALYs lost were estimated to result from post-TB sequelae.
Interpretation In the United States, a substantial fraction of the life-years and QALYs lost from TB are attributable to post-TB sequelae. Evidence is needed on approaches to prevent and repair post-TB lung damage, in the context of frequent co-prevalent health conditions.
Funding CDC.
Evidence before this study Individuals surviving TB disease may experience reduced quality-of-life and elevated mortality rates, due to sequelae of the TB episode and pre-existing factors. We reviewed published literature to identify studies quantifying the impact of post-TB sequelae on life expectancy or other summary measures of health attainment. Using the following search terms: (tuberculosis) AND (“post-TB” OR “post-tuberculosis” OR “sequelae” OR “TB survivor” OR “pulmonary impairment” OR “delayed mortality”) AND (“life expectancy” OR “QALYs” OR “life years” OR “DALYs” OR “years of life lost”), we searched PubMed since inception until October 8 2024, without language restriction. Of the studies identified, most estimated health losses attributable to TB and post-TB in high-burden settings. Studies conducted in the United States reported results for specific geographic areas or trial populations, with estimates of the average life-years lost per TB case ranging from 1.5 to 7.0 years.
Added value of this study For individuals developing TB in the United States, average life expectancy after TB diagnosis was estimated to be 30.3 (95% uncertainty interval: 29.9, 30.7) years, as compared to 32.3 (31.9, 32.7) years under a counterfactual scenario that estimated lifetime outcomes without TB. On average, TB was estimated to reduce life expectancy by 2.03 (1.84, 2.21) years, or 1.93 (1.69, 2.18) quality-adjusted life years (QALYs). Overall, 41% (35, 46) of life years lost and 48% (42, 54) of QALYs lost were from post-TB sequelae. Per person developing TB, TB-attributable reductions in life expectancy were greatest for 65-74-year-olds versus other age groups, for men versus women, and for American Indian/Alaska Native individuals versus other race/ethnicities.
Implications of all the available evidence In this high-income setting with substantial healthcare resources, TB still represents a major health risk for those who develop the disease. Even for individuals who successfully complete TB treatment, lifetime health outcomes are poorer than for people who never had TB, and almost half of the QALYs lost from TB result from post-TB sequelae.
Competing Interest Statement
This study was funded by the U.S. Centers for Disease Control and Prevention.
Funding Statement
U.S. Centers for Disease Control and Prevention
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of the Harvard T.H. Chan School of Public Health determined that this submission is not human subjects research as defined by DHHS regulations or FDA regulations (IRB22-1328).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos